Organon & Co.
$11.70B- Market cap
- $3.62B
- Debt
- +$8.66B
- Cash
- −$574.00M
Capital structure 29% equity / 71% debt · EV / Revenue 1.88x · EV / EBITDA 9.07x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt cap
Decision snapshot: OGN stock price vs LEGN: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at LEGN's multiple
Needs LEGN P/E.
Implied fair value · at OGN's multiple
Needs EPS (TTM) is negative, OGN P/E.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Multiple discount
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: OGN FY 2025 (ended Dec 31, 2025) · LEGN FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 29% equity / 71% debt · EV / Revenue 1.88x · EV / EBITDA 9.07x
Capital structure 85% equity / 15% debt · EV / Revenue 3.68x
OGN carries the larger enterprise value at $11.70B against $3.79B; OGN trades on the lower EV / Revenue multiple (1.88x vs 3.68x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Organon & Co. · implied price per share
Bear
-$8.75
Base
-$5.98
Bull
-$1.08
Legend Biotech Corp · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
11.52x
—
Net debt / EBITDA
Leverage against operating earnings
6.27x
0.64x
Cash and equivalents
Liquid reserves on the balance sheet
$574.00M
$901.90M
Total debt
Interest-bearing obligations outstanding
$8.66B
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
$711.40M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.